Mirabilis Medical, Inc., the developer of a noninvasive therapeutic ultrasound system with an initial application for the treatment of uterine fibroids, appointed Wayne Poll, MD, as their new CEO.
Dr. Poll trained in urology at The Massachusetts General Hospital before practicing urology for 22 years, focusing on minimally invasive therapy, and in particular, laparoscopic and robotic surgery. He has founded several companies, including his medical practice, a clinical research network, a capitated payment company, and then most recently, Minimally Invasive Devices, Inc., a venture-backed medical device company that developed the FloShield laparoscopic vision system.
The Mirabilis system uses high-resolution ultrasound imaging to localize treatment and a proprietary ultrasound technology to quickly and noninvasively treat tissue deep in the body. The technology is office-based, requires no anesthesia, and takes 10-20 minutes. Dr. Poll believes that office-based high-intensity focused ultrasound delivered by gynecologists could become first-line therapy for women with symptomatic fibroids. The company further believes there are other potential applications within oncology.